• Minor estimate revisions • ARR growth streak untouched • EV/ARR ~2x, '23e EV/EBITDA 19x Q2'23 repo...
• We cut '23e-'25e adj. EBITA by 27-4% • Discontinuation of unprofitable products in full swing • '2...
• Q2'23 report on Tuesday, 25 July • Adding new Furniture & Components segment to estimates.
Redeye states that the Q2 report was very strong with solid underlying KPIs, strong revenues from al...
Redeye comments on Stillfront’s Q2-results which came in above our expectations driven by solid prof...
A 9.2% increase in sales throughout the quarter signifies the robust nature of SSH's subscription mo...
Redeye updates its outlook on Hansa Biopharma anticipating gradual launch support during 2023 and su...
Redeye adjusts our growth assumptions for the second half of 2023e based on strong organic growth ou...
Redeye updates its estimates and valuation following Mentice’s Q2 2023 report.
Redeye retains its positive view of ADDvise following a strong Q2 report in line with the preliminar...
- Operational metrics continue to improve - Executing on its project potential - Bond maturities in ...
• EBITA SEK 198m (-11% vs. ABGSCe, -8% vs. cons) • We expect cons.
- Nettoomsättningen och EBITDA-resultatet kom in starkare än väntat - De återkommande intäkterna ök...
Överraskande bra rapport Som vi redan konstaterat på rapportdagen, så lyckades Orexo leverera en bra...
Q2-resultatet svagare än väntat men visar ändå på styrka i en svår marknad Nettoomsättningen minskad...
• Weakness in Architecture behind negative growth • Long-term negative EBIT revisions of 9% • Needs ...
• Two large regions in Sweden restrict staffing... • .
• 13% sales growth y-o-y, of which half was organic • EBITA margin of 9.
Redeye comments on Tessin’s Q2 results, which showed solid sales numbers but lower profitability tha...
Redeye provides its initial take on Mentice’s Q2 2023 report, which came in broadly above our estima...
